DESTINY-Breast-06 is a phase III trial involving ER+/HER2 low or ultralow (IHC 0 with membrane staining) metastatic breast cancer patients progressing after one or more lines of ET with no previous chemotherapy for metastatic disease. This evidence concerns the gene ESR1 and metastatic neoplasm.